SCHEMBL19785875

SCHEMBL19785875

Cc1cc(CN2CCN(C(=O)OC(C)(C)C)[C@@H](C)C2)c(C)c(NC(=S)NN)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RORC P51449 8/20 0.41
HDAC1 Q13547 1/20 0.38
KCNH2 Q12809 3/20 0.38
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.34
MAP4K4 O95819 1/20 0.34
FPR3 P25089 1/20 0.33
CCR1 P32246 1/20 0.33
GPR65 Q8IYL9 1/20 0.33
GPR35 Q9HC97 1/20 0.33
GPR119 Q8TDV5 2/20 0.33
SETD7 Q8WTS6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19785963 0.91 RORC (0.50) RORCKCNH2PTGDR2FPR3CCR1
SCHEMBL19785971 0.88 RORC (0.41) RORCKCNH2PTGDR2FPR3CCR1
SCHEMBL21354330 0.87 RORC (0.46) RORCKCNH2PTGDR2FPR3CCR1
SCHEMBL19785977 0.83 PTGDR2 (0.37) RORCHDAC1KCNH2LMNANPSR1
SCHEMBL29613552 0.83 RORC (0.59) RORCKCNH2
SCHEMBL21354314 0.83 RORC (0.59) RORCKCNH2
SCHEMBL19785886 0.83 RORC (0.57) RORCKCNH2
SCHEMBL19785594 0.82 HDAC1 (0.41) RORCHDAC1KCNH2PTGDR2MAP4K4
SCHEMBL29613577 0.82 HDAC1 (0.41) RORCHDAC1KCNH2PTGDR2MAP4K4
SCHEMBL29613569 0.81 SETD7 (0.36) RORCHDAC1KCNH2PTGDR2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3484880-B1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA AS (DK) 2020-09-02 EP claimed
US-10934282-B2 Heteroaromatic modulators of the retinoid-related orphan receptor gamma LEO PHARMA A/S (DK) 2021-03-02 US disclosed
US-20200291010-A1 HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA A/S 2020-09-17 US disclosed
EP-3484880-B1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA AS (DK) 2020-09-02 EP disclosed
US-10662181-B2 Heteroaromatic modulators of the retinoid-related orphan receptor gamma LEO PHARMA A/S (DK) 2020-05-26 US disclosed
US-20190284177-A1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA A/S (DK) 2019-09-19 US disclosed
WO-2018011201-A1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA A/S (DK) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291010-A1 HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA RXRA, RORA, NR1H3 RORC 18/4885HDAC1 2374/4885KCNH2 2774/4885
US-10934282-B2 Heteroaromatic modulators of the retinoid-related orphan receptor gamma RXRA, RXRG, RXRB RORC 17/4885HDAC1 1397/4885KCNH2 1887/4885
US-10662181-B2 Heteroaromatic modulators of the retinoid-related orphan receptor gamma RXRA, RXRG, RXRB RORC 17/4885HDAC1 1397/4885KCNH2 1887/4885
US-20190284177-A1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA RXRA, RXRG, RXRB RORC 17/4885HDAC1 1397/4885KCNH2 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.